Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow KROS by emailGet an email when KROS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KROS, unsubscribe in one click. Privacy
📣 What KROS Says Is Next
first half of 2027 · “We look forward to the progression of the Phase 2 clinical trial, and continue to expect to present initial data in the first half of 2027.” Second Quarter 2026 Financial Results Keros reported a net loss of $28.7 million in the second quarter of 2026 as compared to a net loss of $30.7 million in the second quarter of 2025.”
Company press release, Aug 3, 2026 · SEC filing
second half of 2026 · “The Company plans to engage regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with ALS in the second half of 2026. 2025 Financial Results Keros reported a net loss of $23.5 million for the fourth quarter and net income of $87.0 million for the year ended December 31, 2025, as compared to a net loss of $46.0 million for the fourth quarter and a net loss of $187.4 million for the year ended December 31, 2024.”
Company press release, Mar 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full KROS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KROS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.